Vor Biopharma : Bio Corporate Presentation March 2024

Ambition: Curing Blood Cancers through cell and genome engineering

March 2024

Disclaimer

This presentation (the "Presentation") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. ("Vor," "Vor Bio" or the "Company"). The words "aim," "anticipate," "believe," "can," "could," "design," "enable" "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "project," "should," "target," "towards," "will," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this Presentation include those regarding the feasibility of a trem-cel (formerly VOR33) transplant to be successfully manufactured, to engraft normally, to maintain blood counts following treatment with Mylotarg following allogeneic hematopoietic cell transplant and to be well tolerated, the potential of VCAR33ALLO in

combination with trem-cel as a Treatment System, the potential of trem-cel to enable targeted therapies in the post-transplant setting including Mylotarg and CD33-targetedCAR-Ts, the potential of Vor Bio's platform, Vor Bio's plans, strategies, expectations and anticipated milestones for its preclinical and clinical programs, including the availability and timing of

results from preclinical studies and clinical trials, the timing of regulatory filings, and the timing of dosing patients, Vor Bio's expectations regarding expedited regulatory review of its product candidates as a result of Fast Tracks designation or otherwise, the expected safety profile of Vor Bio's product candidates, cash runway and expected capital requirements, Vor Bio's expectations regarding addressable patient population and reimbursement rates for its product candidates, if approved, and its plans and expectations related to the Company's manufacturing and facilities. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward- looking statements as a result of various factors, including: uncertainties inherent in the initiation, completion of, and availability and timing of results from, preclinical studies and

clinical trials and clinical development of Vor Bio's product candidates; whether preclinical data or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the uncertainty of regulatory approvals to conduct trials or to market products; the success of Vor Bio's in-house manufacturing capabilities and efforts; and

availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements. The interim data for trem-cel presented in this Presentation is based on eight patients and future results for these patients or additional patients may not produce the same or consistent results. These and other risks are described in greater detail under the caption "Risk Factors" included in Vor Bio's most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this Presentation speak only as of the date of this Presentation, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

Certain information contained in this Presentation relates to or is based on studies, publications, surveys and other data obtained from third party sources and Vor Bio's own internal

estimates and research. While we believe these third-party sources to be reliable as of the date of this Presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third party sources. In addition, there can be no guarantee as to the accuracy or reliability of

any assumptions or limitations that may be included in such third-party information. While we believe our own internal research is reliable, such research has not been verified by any independent source.

2

Our Vision: Cure Blood Cancers Through Cell and Genome Engineering

Unique Approach

Shielded stem cell transplants enabling targeted therapy

VCAR33ALLO	Trem-cel
CD33-directed	Positive POC demonstrated
novel transplant donor	in AML with shielded
CAR-T in clinic with initial	CD33-deleted transplant
data in 2H 2024	Additional data in 2H 2024

$137M as of Dec. 31, 2023 Cash runway into 2H 2025

In-house GMP

Clinical Manufacturing

Reliable process with rapid

release time

3

AML is a Common Leukemia with High Unmet Need

20,000 new cases/year (US)2

(10% of new blood cancer cases)2

Standard of Care is Transplantation

Replace Diseased Bone Marrow with Healthy Donor Cells

Relapse

10,000 deaths/year (US)2

(20% of blood cancer deaths)2

Relapse Despite Transplantation

is still common in AML patients

0.8Post-transplant Incidence of Relapse1

Measurable Residual Disease (MRD) positive

	3	3
1	2	3	4
Conditioning	Harvest	Transplant	Watchful Waiting

Incidence of

0.6

0.4

Active disease

MRD negative

Toxic therapies	Mobilize and collect	Infuse stem cells	Monitor for relapse;
to kill existing	stem cells from	into patient to	any follow-up
bone marrow	matched healthy	restore the blood	treatment will damage
	donor	system	the transplant

Cumulative

0.2

0.0

0

1

2

Years Since HCT

HCT, Hematopoietic Cell Transplant.

• 1 Araki et al, JCO 2016. 2 LLS 2023

Pipeline Generating Multiple Clinical Readouts over Next 12 Months

	Description		Preclinical	Clinical
							Anticipated Milestones
Program / Trial	Modality	Indication	Discovery/	IND-	Phase 1/2	Phase
Validation	Enabling	2/3
VCAR33ALLO		AML					Initial data expected in the
(healthy transplant donor	CD33-directed transplant donor CAR-T	Post-
				second half of 2024
CAR-T) / VBP301		transplant
		AML					Clinical update in second half of
Trem-cel + Mylotarg /	Shielded CD33-deleted transplant +					2024
VBP101	CD33-directed ADC
MDS
Trem-cel + VCAR33	Shielded CD33-deleted transplant +	AML					IND filing following initial
Treatment System	CD33-directed transplant donor CAR-T					trem-cel and VCAR33ALLO data
CD33-CLL1 Treatment	Multi-specificCAR-T	AML
System	Multiplex-edited shielded transplant	AML

5

Cell Therapies Designed to Synergize to Potentially Cure AML

VCAR33ALLO

Healthy transplant donor CD33-directed

CAR-T

Trem-cel

Shielded CD33-deleted

stem cell transplant

Vor Bio Treatment

System

A shielded healthy marrow

co-existing with a

potent, persistent CAR-T

6

VCAR33ALLO: Healthy Transplant Donor CAR-T

VCAR33ALLO

Healthy transplant donor

CD33-directed

CAR-T

7

A New Way of Generating CAR-T Therapy

Traditional Approaches

Autologous cells	Allogeneic cells
(derived from patient)	(off-the-shelf)

Exhausted, depleted T cells	Poor expansion and persistence
High manufacturing failure	Poorer clinical durability

Vor Bio Approach

Transplant Donor Cells

T cells exactly matched to patient's new immune system, more likely to persist

Stem-like,CAR-T cells more likely to expand and less prone to exhaustion

8

Vor Bio's T Cell Manufacturing Process Preserves Stemness

T Cell Phenotype from VCAR33ALLO Process

100

90	Effector (TEM, TEMRA)
80
70	Central Memory (TCM)
60		Stem-like,
50
	long-lived
40
Stem Memory (TSCM)	cells capable
30
of self-
20		renewal
10
0
CD4+	CD8+

Rapid ~7-day process to preserve stemness

Transplant donor cells

VCAR33ALLO

9

VBP301: VCAR33ALLO Phase 1/2 Clinical Trial

Patient Journey	Enroll	VCAR33ALLO Infusion
MRD+ or relapsed AML		Arm A: Blasts ≥ 5%
following SOC transplant or
	Lymphodepletion
trem-cel transplant		Arm B: MRD+

3x3 dose escalation starting at 1 x 106 CAR+ cells/kg

Prior TransplantDonor	Consent	Collect	VCAR33ALLO
		Manufacturing
		~7-day process

First patient treated in Jan 2024 with initial data expected in 2H 2024

Day 28 Follow-up

2nd transplant

if required

Key Endpoints

01 Safety

02 Expansion, persistence

03 Disease control/response

10 Most clinical trial sites overlap with VBP101 trem-cel study